niostem Secures $360K Pre-Seed Funding to Revolutionize Hair Regeneration Technology

niostem, formerly known as Mane Biotech, is delighted to announce that it has successfully raised $360,000 in funding to further accelerate its mission of developing innovative technologies that unlock the body’s regenerative potential. Focused on revolutionizing the approach to common hair loss and pattern baldness, niostem’s breakthrough technology centers on its smart wearable device, nio1, which promises to stop hair loss in as little as three months and actively support hair regrowth from the six-month mark. This funding will provide critical financial support to expand research and development initiatives, optimize the nio1 device’s design, and enhance clinical trials to validate its efficacy and safety further. By doubling down on its commitment to empowering customers to live healthier lives, niostem is poised to transform how individuals combat hair loss, offering a non-invasive, technologically advanced solution that is grounded in regenerative science. The latest infusion of capital will also facilitate strategic partnerships, bolster manufacturing capabilities, and ensure compliance with regulatory standards—key steps that will enable the company to scale its operations and deliver the nio1 wearable device to a broader market. With a focus on innovation, quality, and patient outcomes, niostem is setting new benchmarks in the biotech industry and reinforcing its position as a pioneer in regenerative health technologies. The company is excited about the future possibilities this funding will unlock, paving the way for a more confident, healthier, and vibrant community of customers who can now look forward to a promising solution in the fight against hair loss.